http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013520424-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2011-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013520424-A |
| titleOfInvention | Sodium 4-{[9-chloro-7- (2-fluoro-6-methoxyphenyl) -5H-pyrimido [5,4-d] [2] benzoazepin-2-yl] amino} -2-methoxybenzoate Crystal form |
| abstract | The present invention relates to a compound of formula (I) or a crystalline form thereof or a solvate thereof, a pharmaceutically effective amount of a compound of formula (I) or a crystalline form thereof or a solvate thereof and at least one pharmaceutical A solid pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula (I) for treating a patient suffering from or susceptible to a disease, disorder or condition mediated by Aurora kinase or It relates to the use of the crystalline form or their solvates and to processes relating thereto. |
| priorityDate | 2010-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 189.